Nucro-Technics offers the most complete range of services for the testing of cannabis for medical purposes as defined by the Cannabis Act which came into effect on October 17, 2018.  Through the Controlled Drugs and Substances Act, Nucro-Technics has been testing cannabis / marijuana,  (d9-THC, d8-THC, Cannabidiol, and Cannabinol) for decades across many different formulation types. If you are looking for current Cannabis Regulations & Guides (including those issued but not yet published on Health Canada’s website), click here.

Marijuana Testing studies conducted at Nucro-Technics are compliant with the Cannabis Act.  These studies cover all of the tests specified in Part 6 of the regulations and are used to support the release product to market and to ensure its safety to patients.

Nucro-Technics has extensive experience with Marijuana / Cannabis testing that goes back decades in the testing synthetic delta 9-tetrahydrocannibnol (delta-9-THC). Because Nucro-Technics’ main line of business is to conduct regulatory testing for pharmaceutical companies and biotech companies, we have an Establishment License that shows compliance to pharmaceutical Good Manufacturing Practice (GMP) regulations, as well as a Narcotics License from the Office of Controlled Substances. Nucro-Technics conducts quality work using validated methods that are compliant with Health Canada, FDA, and European regulations. This provides peace of mind to companies and individuals that testing will be done appropriately and professionally.

Nucro-Technics accepts samples for testing activities from authorized Licensed Producers (LPs), healthcare organizations, pharmaceutical companies, and individuals who are approved by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR) or the Cannabis Act. Nucro-Technics also accepts samples for research & development activities (in vivo, in vitro, and chemical) and for pre-clinical studies from entities that are qualified and approved by their local regulatory bodies, such as the Office of Controlled Substances, the FDA, and the DEA.

These in vitro, in vivo, and pre-clinical studies are performed in an effort to expand on the potential therapeutic benefits of cannabinoids and involve investigating the safety, pharmacokinetics, and metabolism of these compounds. Examples of the types of cannabinoid studies that are typically performed at Nucro-Technics include the topical administration of cannabinoids by patches and creams to rodents and Göttingen minipigs.  Other studies that have been conducted involved oral and IV administration of both lipid formulations of cannabis oil as well as and purified cannabinoids to rodent and canine models.  Nucro-Technics routinely performs bioanalysis of study samples across various matrices in both pre-clinical and clinical studies.

While the pharmacokinetics of cannabinoids in humans by smoking cannabis is well-represented in literature, this data does not provide information on partially purified cannabinoid components in novel formulations, which is currently the products of most interest.  This data also typically does not represent routes of administration other than inhalation.  The additional studies performed at Nucro-Technics aim to fill in these research gaps.

While Nucro-Technics is licensed appropriately for the testing of marijuana, the organization does not grow, distribute, or sell cannabis.